𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Response to 5-azacytidine in patients with refractory acute nonlymphocytic leukemia and association with chromosome findings

✍ Scribed by Richard A. Larson; Donald L. Sweet; Harvey M. Golomb; Joseph R. Testa; Janet D. Rowley

Publisher
John Wiley and Sons
Year
1982
Tongue
English
Weight
370 KB
Volume
49
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Pilot study of 5-azacytidine (5-AZA) and
Pilot study of 5-azacytidine (5-AZA) and carboplatin (CBDCA) in patients with relapsed/refractory leukemia
✍ Kritz, Alan D.; Raptis, George; Menendez-Botet, Celia; Maslak, Peter; Jakubowski πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 481 KB πŸ‘ 1 views

5-azacytidine (5-AZA) and carboplatin (CBDCA) are two agents which have demonstrated antileukemic activity In a number of phase 1-11 trials. Their mechanisms of action and pharmacology related to cell resistance suggested sultabiiity for combination therapy. The aim of this pilot study was to evalua

Possible association between Budd-Chiari
Possible association between Budd-Chiari syndrome and gemtuzumab ozogamicin treatment in a patient with refractory acute myelogenous leukemia
✍ MevlΓΌt Kurt; Ali Shorbagi; Kadri Altundag; Tamer Elkiran; Ibrahim GΓΌllΓΌ; Emin Ka πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 86 KB πŸ‘ 2 views

## Abstract Gemtuzumab ozogamicin (GO; CMA‐676; Mylotargβ„’) is a chemotherapeutic agent approved for the treatment of CD33‐positive acute myelogenous leukemia in patients of age 60 years or older after first relapse. Hepatic veno‐occlusive disease has been reported to develop as a late complication